TABLE 1.
Origins and antimicrobial susceptibilities of GBS isolates
| Strain or categorya and isolate no. | Date of isolation (mo/day/yr) | Patient statusb | Wardc | Age (yr) | Sexd | Specimen typee | Serotype | CTB inhibition zone diameterf (mm) | MIC (μg/ml) ofg: |
||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CEC | PEN | AMP | CTM | CTX | CRO | CDN | FEP | CFM | ZOXh | MEM | ERY | CLR | CLI | LVX | TET | VAN | |||||||||
| 2603V/R ATCC BAA-611 | V | 19.0 | 1 | 0.06 | 0.12 | 0.5 | ≤0.06 | 0.12 | ≤0.06 | ≤0.5 | 0.5 | 0.064 | ≤0.12 | ≤0.12 | ≤0.12 | ≤0.12 | 0.5 | >4 | 0.5 | ||||||
| NEM316 ATCC 12403 | III | 18.7 | 1 | 0.06 | 0.12 | ≤0.5 | ≤0.06 | ≤0.12 | ≤0.06 | ≤0.5 | 0.5 | 0.094 | ≤0.12 | ≤0.12 | ≤0.12 | ≤0.12 | 0.5 | >4 | 0.5 | ||||||
| PRGBS | |||||||||||||||||||||||||
| A1 | 12/5/2011 | Out | EM | 99 | M | TTA | Ib | No zone | 16 | 0.5 | 0.25 | >4 | 1 | 0.5 | 0.5 | 1 | 1 | >32 | 0.5 | >1i | >1i | >1i | >8 | ≤0.5 | 0.5 |
| A2 | 1/12/2012 | In | IM 2C | 77 | M | TTA | Ib | No zone | 16 | 0.5 | 0.25 | 4 | 1 | 1 | 0.5 | 1 | >1 | >32 | 0.25 | 1i | 1i | >1i | >8 | ≤0.5 | 0.5 |
| CTBr PSGBS | |||||||||||||||||||||||||
| B1 | 1/8/2012 | In | IM 2C | 77 | M | TTA | Ib | No zone | 8 | 0.12 | 0.12 | 2 | 0.25 | 0.25 | 0.12 | ≤0.5 | 1 | 1.5 | ≤0.12 | ≤0.12 | ≤0.12 | ≤0.12 | >8 | ≤0.5 | 0.5 |
| B2 | 5/16/2011 | In | S 4C | 80 | M | Pus (oral cavity) | Ib | No zone | 16 | 0.06 | 0.12 | 1 | 0.12 | ≤0.12 | ≤0.06 | ≤0.5 | 1 | 0.75 | ≤0.12 | >1j | >1j | >1j | >8 | >4 | 0.5 |
| B3 | 9/12/2011 | In | IM 2C | 68 | M | TTA | Ib | No zone | 16 | 0.06 | 0.12 | 1 | 0.12 | ≤0.12 | ≤0.06 | ≤0.5 | 1 | 0.75 | ≤0.12 | ≤0.12 | ≤0.12 | ≤0.12 | >8 | ≤0.5 | 0.5 |
| B4 | 9/14/2011 | In | NS 3B | 92 | F | Urine | Ib | No zone | 8 | 0.06 | 0.12 | 0.5 | 0.12 | ≤0.12 | ≤0.06 | ≤0.5 | 0.5 | 0.75 | ≤0.12 | ≤0.12 | ≤0.12 | ≤0.12 | >8 | ≤0.5 | 0.5 |
| B5 | 10/18/2011 | In | IM 2C | 64 | M | TTA | Ib | No zone | 8 | 0.06 | 0.12 | 2 | 0.25 | ≤0.12 | 0.12 | ≤0.5 | 1 | 1.5 | ≤0.12 | ≤0.12 | ≤0.12 | 0.12 | >8 | ≤0.5 | 0.5 |
| B6 | 1/18/2012 | In | IM 4W | 94 | M | TTA | Ib | No zone | 8 | 0.06 | 0.12 | 1 | 0.12 | ≤0.12 | ≤0.06 | ≤0.5 | 0.5 | 1 | ≤0.12 | >1k | >1k | >1k | >8 | >4 | 0.5 |
| PSGBS | |||||||||||||||||||||||||
| B7 | 10/17/2011 | Out | EM | 73 | M | Urine | Ib | 17.6 | 2 | 0.06 | 0.12 | 1 | 0.12 | ≤0.12 | ≤0.06 | ≤0.5 | 1 | 0.19 | ≤0.12 | ≤0.12 | ≤0.12 | ≤0.12 | >8 | ≤0.5 | 0.5 |
PRGBS, GBS isolates with reduced penicillin susceptibility; CTBr PSGBS, PSGBS with no growth inhibition zones around a ceftibuten disk; PSGBS, penicillin-susceptible GBS.
Out, outpatient; In, inpatient.
S, surgery; IM, internal medicine; NS, neurosurgery; EM, emergency.
M, male; F, female.
TTA, transtracheal aspirate.
Determined by standard disk diffusion test. CTB, ceftibuten.
CEC, cefaclor; PEN, penicillin; AMP, ampicillin; CTM, cefotiam; CTX, cefotaxime; CRO, ceftriaxone; CDN, cefditoren; FEP, cefepime; CFM, cefixime; ZOX, ceftizoxime; MEM, meropenem; ERY, erythromycin; CLR, clarithromycin; CLI, clindamycin; LVX, levofloxacin; TET, tetracycline; VAN, vancomycin.
MIC results of the Etest.
Positive for ermT/R.
Positive for ermB, ermT/R, and mefA/E.
Positive for ermB.